Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-HER2 monoclonal antibody QL1209

A humanized monoclonal antibody directed against the domain II of the extracellular domain of human epidermal growth factor receptor 2 (HER2; ErbB2; HER-2), with potential antineoplastic activity. Upon administration, anti-HER2 monoclonal antibody QL1209 targets and binds to HER2 on HER2-expressing tumor cells. This prevents HER2-mediated signaling and may lead to an inhibition of proliferation in HER2-expressing tumor cells. HER2, a tyrosine kinase receptor, is overexpressed by many cancer cell types.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Code name:	QL 1209 QL-1209 QL1209

anti-HER2 monoclonal antibody QL1209

Search NCI's Drug Dictionary